环丝氨酸在治疗耐多药肺结核患者中的不良反应分析  

Analysis of adverse drug reactions of Cycloserine in the treatment of patients with multi-drug resistant pulmonary tuberculosis

作　　者：程武[1] 谭守勇[2] 李艳[1] 邝浩斌[1] 

机构地区：[1]广州市胸科医院肺结核科,510095 [2]广州市胸科医院呼吸疾病国家重点实验室,510095

出　　处：《结核病与肺部健康杂志》2015年第4期247-249,共3页Journal of Tuberculosis and Lung Health

基　　金：“十二五”国家科技重大专项（2012ZX10004-903）;2015年广州市医药卫生科技重大项目（20151A031002）

摘　　要：目的 观察环丝氨酸在治疗耐多药肺结核患者中的不良反应,为临床安全用药提供决策依据.方法 回顾性分析我院治疗耐多药肺结核患者中使用环丝氨酸的情况,总结发生不良反应的类型、发生时限、处理后的结果.患者总例数为61例,其中,可统计的使用含环丝氨酸方案治疗的耐多药患者50例.患者年龄在18～78岁之间,中位年龄42.5岁.结果 多达84.0％（42/50）的患者能完成长达24个月的疗程.发生不良反应患者8例,大多发生在神经、精神方面.不良反应发生率16.0％（8/50）,此8例患者均在出现不良反应后停用了环丝氨酸,停药率16.0％.停药后不良反应均缓解.结论 环丝氨酸是比较安全的治疗耐多药肺结核的药物.在使用环丝氨酸的过程中,需要警惕神经、精神方面的症状.Objective To observe the adverse reactions of Cycloserine in the treatment of patients with multi- drug resistant pulmonary tuberculosis, and provide the basis for clinical safe medication. Methods To review the use of Cycloserine in the treatment of patients with multi-drug resistant pulmonary tuberculosis in our hospital, summarize the types of adverse reactions, the occurrence time and the processing results. The total number of patients was 61 ,and the number of patients with multi-drug resistant pulmonary tuberculosis treated with Cycloserine was 50 cases. The patients were aged between 18 and 78 years old, and the median age was 42. 5 years. Results Up to 84. 0% （42/50） of patients can complete the 24-months treatment course. Adverse reactions occurred in 8 cases, most of them occurred in the nervous and mental aspects. The incidence rate of adverse reactions was 16.0%（8/50）, and the 8 patients discontinued the use of Cycloserine after the adverse reactions occur with the discontinua- tion rate of 16.0%. Those adverse reactions were all relieved after stopping the drug. Conclusion Cycloserine is a relatively safe drug for the treatment of multi-drug resistant tuberculosis. But in the course of using Cycloserine, need to be alert to the nervous and mental symptoms.

关 键 词：环丝氨酸 结核 肺 抗药性 多种 细菌 药物毒性 

分 类 号：R521[医药卫生—内科学]